solanezumab
Solanezumab is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials. — Wikipedia
Clinical trial activity
12 trials · 8 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2006 (NCT00329082)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinBINDING AGENT
Beta amyloid A4 protein binding agent
Targets the mid-region of the neurotoxic Amyloid ß peptide after it is produced. Neutralises disease-relevant aggregated forms of amyloid-beta. Amyloid ß is an early biomarker of Alzheimer's disease pathology and the major component of plaques found in AD-affected brain.
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
APP other
Targets the mid-region of the neurotoxic Amyloid ß peptide after it is produced. Neutralises disease-relevant aggregated forms of amyloid-beta. Amyloid ß is an early biomarker of Alzheimer's disease pathology and the major component of plaques found in AD-affected brain.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSolanezumab ↗
- ChEMBLCHEMBL1743072 ↗
Also known as
- ly2062430
- ly2062430
- ly2062430
- ly 2062430
- ly-2062430
- ly-2062430
- solanezumab
- solanezumab
- solanezumab
- solanezumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02760602 | Phase 3 | Jun 1, 2016 | Eli Lilly |
| NCT02614131 | Phase 1 | Dec 1, 2015 | Eli Lilly |
| NCT02008357 | Phase 3 | Feb 1, 2014 | Alzheimer's Therapeutic Research Institute, Eli Lilly |
| NCT01900665 | Phase 3 | Jul 1, 2013 | Eli Lilly |
| NCT04623242 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2012 | Accelerating Medicines Partnership, Alzheimer's Association, Avid Radiopharmaceuticals, Eli Lilly, National Institute on Aging (NIA), Roche, Washington University in St. Louis |
| NCT01760005 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2012 | Accelerating Medicines Partnership, Alzheimer's Association, Avid Radiopharmaceuticals, Eli Lilly, National Institute on Aging (NIA), Roche, Washington University in St. Louis |
| NCT01127633 | Phase 3 | Dec 1, 2010 | Eli Lilly |
| NCT01148498 | Phase 2 | Aug 1, 2010 | Eli Lilly |
| NCT00905372 | Phase 3 | May 1, 2009 | Eli Lilly |
| NCT00904683 | Phase 3 | May 1, 2009 | Eli Lilly |
| NCT00749216 | Phase 2 | Sep 1, 2008 | Eli Lilly |
| NCT00329082 | Phase 2 | May 1, 2006 | Eli Lilly |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 12 | 10 | 3 | 2006 |
| Accelerating Medicines Partnership | Academic/Hospital | 2 | 0 | 1 | 2012 |
| Alzheimer's Association | Academic/Hospital | 2 | 0 | 1 | 2012 |
| Avid Radiopharmaceuticals | For profit | 2 | 0 | 1 | 2012 |
| National Institute on Aging (NIA) | Government | 2 | 0 | 1 | 2012 |
| Roche | For profit | 2 | 0 | 1 | 2012 |
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Alzheimer's Therapeutic Research Institute | Academic/Hospital | 1 | 0 | 1 | 2014 |